Monitoring Treatment Response in Rectal Cancer through Circulating Tumor Cell Dynamics: A Pilot Clinical Study
Journal of Surgical Oncology · 2025
DOI: 10.1002/jso.70073 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Peter Ihnát und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University Hospital Ostrava, Ostrava, Czech Republic. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Rectal Neoplasms, Adenocarcinoma. Die Arbeit nennt 24 Literaturangaben. Gefördert von: This study was supported by Ministry of Health, Czech Republic - conceptual development of research organization (1/RVO-FNOs/2023)..
Abstract (Originalsprache)
Background
Circulating tumor cells (CTCs) are increasingly recognized as a minimally invasive biomarker with significant potential in oncologic monitoring and prognostication. This study aimed to assess the dynamics of CTC levels in patients with rectal cancer undergoing multimodal treatment and evaluate their potential role in therapeutic decision‐making.
Methods
We conducted a prospective, observational study of 56 patients with histologically confirmed rectal adenocarcinoma. Patients underwent either primary surgical resection or neoadjuvant chemoradiotherapy (CRT) followed by surgery. Peripheral blood samples were collected at defined intervals and analyzed using the CytoTrack CT11™ system to detect and quantify CTCs.
Results
Pretreatment CTCs were detected in 16.1% of patients. In the primary surgery group, all preoperatively positive CTC cases became negative postoperatively, although transient positivity was observed in two cases at 1 week post‐surgery. In the CRT group, 35.7% of patients exhibited detectable CTCs during treatment, with complete clearance after surgery. The dynamic change in CTC levels correlated with therapeutic response and potential recurrence risk.
Conclusions
This pilot study highlights the clinical relevance of CTC monitoring in rectal cancer. CTC dynamics appear to reflect treatment efficacy and may serve as an early indicator of response. These findings support the development of a randomized clinical trial comparing rectal cancer treatments with and without neoadjuvant therapy, using CTC trends as a primary outcome measure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University Hospital Ostrava, Ostrava, Czech Republic.
- Institute of Molecular and Translational Medicine, Faculty of Medicine, Palacky University Olomouc, Olomouc, Czech Republic.
- Department of Oncology, University Hospital Ostrava, Ostrava, Czech Republic.
- Department of Surgery, City Hospital Ostrava, Ostrava, Czech Republic.
- Department of Forensic Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Förderung
- This study was supported by Ministry of Health, Czech Republic - conceptual development of research organization (1/RVO-FNOs/2023).
Zitieren
APA
Ihnát, P., Srovnal, J., Stejskal, P., Vidlařová, M., Skácelíková, E., Šnajder, B., Varga, Á., & Ihnát Rudinská, L. (2025). Monitoring Treatment Response in Rectal Cancer through Circulating Tumor Cell Dynamics: A Pilot Clinical Study. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70073
Vancouver
Ihnát P, Srovnal J, Stejskal P, Vidlařová M, Skácelíková E, Šnajder B, et al. Monitoring Treatment Response in Rectal Cancer through Circulating Tumor Cell Dynamics: A Pilot Clinical Study. Journal of Surgical Oncology. 2025. doi:10.1002/jso.70073
BibTeX
@article{Ihnt2025,
author = {Ihnát, Peter and Srovnal, Josef and Stejskal, Pavel and Vidlařová, Monika and Skácelíková, Eva and Šnajder, Branislav and Varga, Ádám and Ihnát Rudinská, Lucia},
title = {Monitoring Treatment Response in Rectal Cancer through Circulating Tumor Cell Dynamics: A Pilot Clinical Study},
journal = {Journal of Surgical Oncology},
year = {2025},
doi = {10.1002/jso.70073}
}
EUVIMED